Role of Apolipoprotein E in Alzheimer’s Disease

  • Vassilis I. Zannis
  • Eleni E. Zanni
  • Savvas C. Makrides
  • Dimitris Kardassis
  • Sergei Aleshkov
Part of the NATO ASI Series book series (NSSA, volume 294)


Alzheimer’s Disease (AD) is a devastating disease which affects the elderly population and is associated with loss of memory (1–3). The prevalence of AD in people over 65 years of age is approximately 5–10%, and for people over 85 is approximately 50% (1). It is estimated that the current annual cost for care of AD patients is $100 billion. Furthermore, it is projected that the number of people affected by AD will increase 4-fold by the year 2030. Clearly, AD is a major public health problem.


Alzheimer Disease Amyloid Protein Precursor Amyloid Plaque Senile Plaque Reactive Astrocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Myers, R.H., Schaefer, E.J., Wilson, P.W.F., D’Agostino, R., Ordovas, J.M., Espino, A., Au, R., White, R.F., Knoefel, J.E., Cobb, J.L., McNulty, K.A., Beiser, A., Wolf, P.A. 1996. Apolipoprotein E,4 association with dementia in a population-based study: The Framingham Study. Amer. Acad. Neur. 46:673–677.Google Scholar
  2. 2.
    Bachman, D.L., Wolf, P.A., Linn, R., Knoefel, J.E., Cobb, J., Belanger, A., D’Agostino, R.B., White, L.R. 1992. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 42:115–119.PubMedCrossRefGoogle Scholar
  3. 3.
    Price, D.L., Sisodia, S.S. 1994. Cellular and molecular biology of Alzheimer’s disease and animal models. Annu. Rev. Med. 45:435–446.PubMedCrossRefGoogle Scholar
  4. 4.
    Goate, A., Chartier-Harlin, M.-C., Mullan, M., et al. 1991. Segregation of a missense mutation in the amyloid precursor protein with familial Alzheimer’s disease. Nature 349:704–706.PubMedCrossRefGoogle Scholar
  5. 5.
    Chartier-Harlin, M.-C., Crawford, F., Houlden, H., et al. 1991. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the β amyloid precursor protein gene. Nature 353:844–846.PubMedCrossRefGoogle Scholar
  6. 6.
    Murrell, J., Farlow, M., Ghetti, B., Benson, M.D. 1991. A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease. Science 254:97–99.PubMedCrossRefGoogle Scholar
  7. 7.
    Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., Lannfeldt., L. 1993. Apathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of β-amyloid. Nature Genet. 1:345–347.CrossRefGoogle Scholar
  8. 8.
    Levy, E., Carman, M.D., Fernandez-Madrid, I.J., Power, M.D., Lieberburg, I., van Duinen, S.G., Bots, G.T.A.M., Luyendijk, W., Frangione, B. 1990. Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science 248:1124–1126.PubMedCrossRefGoogle Scholar
  9. 9.
    Hyman, B.T., West, H.L., Rebeck, G.W., Buldyrev, S.V., Mantegna, R.N., Ukleja, M., Havlin, S., Stanley, H.E. 1995. Quantitative analysis of senile plaques in Alzheimer disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc. Natl. Acad. Sci. USA 92:3586–3590.PubMedCrossRefGoogle Scholar
  10. 10.
    Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J.-F., Bruni, A.C., Montesi, M.P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R.F., Wasco, W., DaSilva, H.A.R., Haines, J.L., Pericak-Vance, M.A., Tanzi, R.E., Roses, A.D., Fraser, P.E., Rommens, J.M., St. George-Hyslop, P.H. 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375:754–760.PubMedCrossRefGoogle Scholar
  11. 11.
    Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D.M., Oshima, J., Pettingell, W.H., Yu, C-E., Jondro, P.D., Schmidt, S.D., Wang, K., Crowley, A.C., Fu, Y-H., Guenette, S.Y., Galas, D., Nemens, E., Wijsman, E.M., Bird, T.D., Schellenberg, G.D., Tanzi, R.E. 1995. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269:973–977.PubMedCrossRefGoogle Scholar
  12. 12.
    Selkoe, D.J. 1996. Amyloid β-protein and the genetics of Alzheimer’s disease. J. Biol. Chem. 271:18295–18298.PubMedGoogle Scholar
  13. 13.
    Selkoe, D.J. 1994. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer’s disease. Annu. Rev. Cell Biol. 10:373–403.PubMedCrossRefGoogle Scholar
  14. 14.
    Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., Roses, A.D. 1993. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:1977–1981.PubMedCrossRefGoogle Scholar
  15. 15.
    Selkoe, D.J. 1991. The molecular pathology of Alzheimer’s disease. Neuron 6:487–498.PubMedCrossRefGoogle Scholar
  16. 16.
    Kidd, M. 1963. Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature 197:192–193.PubMedCrossRefGoogle Scholar
  17. 17.
    Terry, R.D. 1963. The fine structure of neurofibrillary tangles in Alzheimer’s disease. J. Neuropathol. Exp. Neurol. 22:629–641.PubMedCrossRefGoogle Scholar
  18. 18.
    Nukina, N., Ihara, Y. 1986. One of the antigenic determinants of paired helical filaments is related to a tau protein. J. Biochem. 99:1541–1544.PubMedGoogle Scholar
  19. 19.
    Kosik, K.S., Joachim, C.L., Selkoe, D.J. 1986. Microtubule-associated protein, tau, is a major antigenic component of paired helical filaments in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 83:4044–4048.PubMedCrossRefGoogle Scholar
  20. 20.
    Glenner, G.G. 1980. Amyloid deposits and amyloidosis. New Engl. J. Med. 203:1283–1291.CrossRefGoogle Scholar
  21. 21.
    Glenner, G.G., Wong, C.W. 1984. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:885–890.PubMedCrossRefGoogle Scholar
  22. 22.
    Masters, C.L., Multhaup, G., Simms, G., Pottigiesser, J., Martins, R.N., Beyreuther, K. 1985a. Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4:2757–2763.PubMedGoogle Scholar
  23. 23.
    Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grezeschik, K.-H., Multhaup, G., Beyreuther, K., Muller-Hill, B. 1987. The precursor of Alzheimer’s disease amyloid Aβ protein resembles a cell-surface receptor. Nature 325:733–736.PubMedCrossRefGoogle Scholar
  24. 24.
    Ponte, P., Gonzalez-DeWhitt, P., Schilling, J., Miller, J., Hus, D., Greenberg, B., Davis, K., Wallace, W., Lieberburg, I., Fuller, F., Cordeil, B. 1988. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 331:525–527.PubMedCrossRefGoogle Scholar
  25. 25.
    Tanzi, R.E., McClatchey, A.I., Lamperti, E.D., Villa-Komaroff, L.L., Gueslla, J.F., Neve, R.L. 1988. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature 331:528–530.PubMedCrossRefGoogle Scholar
  26. 26.
    Kitaguchi, N., Takahashi, Y., Tolkushima, Y., Shiojiri, S., Ito, H. 1988. Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity. Nature 331:530–532.PubMedCrossRefGoogle Scholar
  27. 27.
    Van Nostrand, W.E., Wagner, S.L., Suzuki, M., Choi, B.H., Farrow, J.S., Geddes, J.W., Cotman, C.W., Cunningham, D.D. 1989. Protease nexin-II, a potent anti-chymotrypsin, shows identity of amyloid β-protein precursor. Nature 341:546–549.PubMedCrossRefGoogle Scholar
  28. 28.
    Oltersdorf, T., Fritz, L.C., Schenk, D.B., Lieberburg, I., Johnson-Wood, K.L., Beattie, E.C., Ward, P.J., Blacher, R.W., Dovey, H.F., Sinha, S. 1989. The secreted form of the Alzheimer’s amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature 341:144–147.PubMedCrossRefGoogle Scholar
  29. 29.
    Smith, R.P., Higuchi, D.A., Broze, Jr., G.J. 1990. Platelet coagulation factor Xia-inhibitor, a form of Alzheimer amyloid precursor protein. Science 248:1126–1128.PubMedCrossRefGoogle Scholar
  30. 30.
    Schmaier, A., Dahl, L., Hasan, A., Cines, D., Bauer, K., Van Nostrand, W. 1995. Factor IXa inhibition by protease nexin-2/amyloid β-protein precursor on phospholipid vesicles and cell membranes. Biochemistry 34:1171–1178.PubMedCrossRefGoogle Scholar
  31. 31.
    Kounnas, M.Z., Moir, R.D., Rebeck, G.W., Bush, A.I., Argraves, W.S., Tanzi, R.E., Hyman, B.T., Strickland, D.K. 1995. LDL receptor-related protein, a multifunctional apoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation. Cell 82:331–340.PubMedCrossRefGoogle Scholar
  32. 32.
    Saitoh, T., Sundsmo, M., Roch, J.-M., Kimura, N., Cole, G., Schubert, D., Oltersdorf, T., Schenk, D.B. 1989. Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts. Cell 58:615–622.PubMedCrossRefGoogle Scholar
  33. 33.
    Van Nostrand, W.E., Schmaier, A.H., Farrow, J.S., Cunningham, D.D. 1990. Protease nexin-II (amyloid beta-protein precursor): A platelet alpha-granule protein. Science 248:745–748.PubMedCrossRefGoogle Scholar
  34. 34.
    Klier, F.G., Cole, G., Stallcup, W., Schubert, D. 1990. Amyloid β-protein precursor is associated with extracellular matrix. Brain Res. 515:336–342.PubMedCrossRefGoogle Scholar
  35. 35.
    Selkoe, D.J., Podisny, M.B., Joachim, C.L., Vickers, E.A., Lee, G., Oltersdorf, T. 1988. β-Amyloid precursor protein of Alzheimer disease occurs as 110-to 135-kilodalton membrane-associated proteins in neural and non-neural tissues. Proc. Natl. Acad. Sci. USA 85:7341–7345.PubMedCrossRefGoogle Scholar
  36. 36.
    Esch, F.S., Keim, P.S., Beattie, E.C., Blacher, R.W., Culwell, A.R., Oltersdorf, T., McClure, D., Ward, P.J. 1990. Cleavage of amyloid β peptide during constitutive processing of its precursor. Science 248:1122–1124.PubMedCrossRefGoogle Scholar
  37. 37.
    Sisodia, S.S., Koo, E.H., Beyreuther, K., Unterbeck, A., Price, D.L. 1990. Evidence that beta-amyloid protein in Alzheimer’s disease is not derived by normal processing. Science 248:492–495.PubMedCrossRefGoogle Scholar
  38. 38.
    Seubert, P., Oltersdorf, T., Lee, M.G., et al. 1993. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide. Nature 361:260–262.PubMedCrossRefGoogle Scholar
  39. 39.
    Furukawa, K., Sopher, B.L., Rydel, R.E., Begley, J.G., Pham, D.G., Martin, G.M., Fox, M., Mattson, M.P. 1996. Increased activity-regulating and neuroprotective efficacy of “-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 67:1882–1896.PubMedCrossRefGoogle Scholar
  40. 40.
    Haass, C., Koo, E.H., Mellon, A., Hung, A.Y., Selkoe, D.J. 1992. Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357:500–503.PubMedCrossRefGoogle Scholar
  41. 41.
    Golde, T.E., Estus, S., Younkin, L.H., Selkoe, D.J., Younkin, S.G. 1992. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255:728–730.PubMedCrossRefGoogle Scholar
  42. 42.
    Ripellino, J.A., Vassilacopoulou, D., Robakis, N.K. 1994. Solubilization of full-length amyloid precursor proteins from PC12 cell membranes. J. Neurosci. Res. 39:211–218.PubMedCrossRefGoogle Scholar
  43. 43.
    Bhasin, R., Gregori, L., Morozov, I., Goldgaber, D. 1994. A processing pathway for amyloid β-protein precursor generates a secreted form with an intact carboxyl terminus. Amyloid: Int. J. Exp. Clin. Invest. 1:221–231.Google Scholar
  44. 44.
    Conn, K.J., Papastoitsis, G., Meckelein, B., Abraham, C.R. 1994. Identification of full length β-amyloid precursor protein in human neuronal and non-neuronal cell culture supernatant: A possible extracellular source for the generation of Aβ. Amyloid: Int. J. Exp. Clin. Invest. 1:232–239.Google Scholar
  45. 45.
    Haass, C., Schlossmacher, M.G., Hung, A.Y., et al. 1992. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359:322–325.PubMedCrossRefGoogle Scholar
  46. 46.
    Shoji, M., Golde, T.E., Ghiso, J., et al. 1992. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258:126–129.PubMedCrossRefGoogle Scholar
  47. 47.
    Seubert, P., Vigo-Pelfrey, C., Esch, F., et al. 1992. Isolation and quantification of soluble Alzheimer’s β-peptide from biological fluids. Nature 359:325–327.PubMedCrossRefGoogle Scholar
  48. 48.
    Busciglio, J., Gabuzda, D.H., Matsudaira, P., Yankner. B.A. 1993. Generation of β-amyloid in the secretory pathway in neuronal and non-neuronal cells. Proc. Natl. Acad. Sci. USA 90:2092–2096.PubMedCrossRefGoogle Scholar
  49. 49.
    Abraham, C.R., Selkoe, D.J., Potter, H. 1988. Immunochemical identification of the serine protease inhibitor, ar-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease. Cell 52:487–501.PubMedCrossRefGoogle Scholar
  50. 50.
    Abraham, C.R., Shirahama, T., Potter, H. 1990. a1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of a1-antichymotrypsin. Neurobiol. Aging 11:123–129.PubMedCrossRefGoogle Scholar
  51. 51.
    Pasternak, J.M., Abraham, C.R., Van Dyke, B.J., Potter, H., Younkin, S.G. 1989. Astrocytes in Alzheimer’s disease gray matter express al-antichymotrypsin mRNA. Am. J. Pathol. 135:827–833.Google Scholar
  52. 52.
    Koo, E.H., Abraham, C.R., Potter, H., Cork, L.C., Price, D.L. 1991. Developmental expression of a1-antichymotrypsin in brain may be related to astrogliosis. Neurobiol. Aging 12:495–501.PubMedCrossRefGoogle Scholar
  53. 53.
    Eikelenboom, P., Stam, F.C. 1982. Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study. Acta Neuropathol. 57:239–242.PubMedCrossRefGoogle Scholar
  54. 54.
    Itagaki, S., McGeer, P.L., Akiyama, H., Zhu, S., Selkoe, D.J. 1989. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer’s disease. J. Neuroimmunol. 24:173–182.PubMedCrossRefGoogle Scholar
  55. 55.
    Eddieston, M., Mucke, L. 1993. Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience 54:15–36.CrossRefGoogle Scholar
  56. 56.
    Siman, R., Card, J.P., Nelson, R.B., Davis, L.G. 1989. Expression of β-amyloid precursor protein in reactive astrocytes. Neuron 3:275–285.PubMedCrossRefGoogle Scholar
  57. 57.
    Abraham, C.R., Kanemaru, K., Mucke, L. 1993. Expression of cathepsin G-like and a1-antichymotrypsin-like proteins in reactive astrocytes. Brain Res. 621:222–232.PubMedCrossRefGoogle Scholar
  58. 58.
    Razzaboni, B.L., Papastoitsis, G., Koo, E.H., Abraham, C.R. 1992. A calcium-stimulated serine protease from monkey brain degrades the β-amyloid precursor protein. Brain Res. 589:207–216.PubMedCrossRefGoogle Scholar
  59. 59.
    Whitson, J.S., Selkoe, D.J., Cotman, C.W. 1989. Amyloid β protein enhances the survival of hippocampal neurons in vitro. Science 243:1488–1490.PubMedCrossRefGoogle Scholar
  60. 60.
    Pike, C.J., Burdick, D., Walencewicz, A.J., Glabe, C.G., Cotman, C.W. 1993. Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13:1676–1687.PubMedGoogle Scholar
  61. 61.
    Pike, C.J., Cummings, B.J., Monzavi, R., Cotman, C.W. 1994. β amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer’s disease. Neuroscience 63:517–531.PubMedCrossRefGoogle Scholar
  62. 62.
    Lorenzo, A., Yankner B. 1994. β amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer’s disease. Proc. Nat. Acad. Sci. USA 91:12243–12247.PubMedCrossRefGoogle Scholar
  63. 63.
    Meda, L., Lasatella, M.A., Szendru, G.I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., Rossi, F. 1995. Activation of microglial cells by β amyloid protein and interferon-(. Nature 374:647–650.PubMedCrossRefGoogle Scholar
  64. 64.
    Thomas, T., Thomas, G., McLendon, C., Sutton, T., Mullan, M. 1996. β amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380:168–171.PubMedCrossRefGoogle Scholar
  65. 65.
    Yankner, B.A., Duffy, L.K., Kirschner, D.A. 1990. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science 250:279–282.PubMedCrossRefGoogle Scholar
  66. 66.
    Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., Zhao, J. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523–527.PubMedCrossRefGoogle Scholar
  67. 67.
    Zannis, V.I., Kardassis, D., Zanni, E.E. 1993. Genetic mutations affecting human lipoproteins, their receptors and their enzymes. Adv. Hum. Genetics (H. Harris and K. Hirschorn, eds.) Plenum Press, NY. Vol. 21, pp. 145–319.CrossRefGoogle Scholar
  68. 68.
    Rall, S.C., Weisgraber, K.H., Mahley, R.W. 1981. Human apolipoprotein E: The complete amino acid sequence. J. Biol. Chem. 257:4171–4178.Google Scholar
  69. 69.
    Zannis, V.I., McPherson, J., Goldberger, G., Karathanasis, S.K., Breslow, J.L. 1984. Synthesis, intracellular processing and signal peptide of human apoE. J. Biol. Chem. 259:5495–5499.PubMedGoogle Scholar
  70. 70.
    Paik, Y.K., Chang, D.J., Reardon, C.A., Davies, G.E., Mahley, R.W., Taylor, J.M. 1985. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc. Natl. Acad. Sci USA 82:3445–3451.PubMedCrossRefGoogle Scholar
  71. 71.
    Das, H.K., McPherson, J., Bruns, G.A.P., Karathanasis, S.K., Breslow, J.L. 1985. Isolation, characterization and mapping to chromosome 19 of the human apolipoprotein E gene. J. Biol. Chem. 260:6240–6246.PubMedGoogle Scholar
  72. 72.
    McLean, J.W., Elshourbagy, N.A., Chang, D.J., Mahley, R.W., Taylor, J.M. 1984. Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant. J. Biol. Chem. 259:6498–7504.PubMedGoogle Scholar
  73. 73.
    Wilson, C., Wardell, M.R., Weisgraber, K.H., Mahley, R.W., Agard, D.A. 1991. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252:1817–1822.PubMedCrossRefGoogle Scholar
  74. 74.
    Wilson C., Agard A., Mahley, R.W., Weisgraber, K.H. 1993. Crystal structures of the common apolipoprotein E variants: Insights into functional mechanisms. NATO ASI Series. Vol. II, 73:81–96.Google Scholar
  75. 75.
    Wilson, C. et al. 1994. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure 2:713–718.PubMedCrossRefGoogle Scholar
  76. 76.
    Dong, L-M., Wilson, C., Wardell, M.R., Simmons, T., Mahley, R.W., Weisgraber, K.H., Agard, D.A. 1994. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269:22358–22365.PubMedGoogle Scholar
  77. 77.
    Nolte, R.T., Atkinson, D. 1992. Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys. J. 63:1221.PubMedCrossRefGoogle Scholar
  78. 78.
    Newman, T.C., Dawson, P.A., Rudel, L.L., Williams, D.L. 1985. Quantitation of apolipoprotein E mRNA in the liver and peripheral tissues of nonhuman primates. J. Biol. Chem. 260:2452–2457.PubMedGoogle Scholar
  79. 79.
    Skene, J.H.P., Shooter, E.M. 1983. Denervated sheath cells secrete a new protein after nerve injury. Proc. Natl. Acad. Sci. USA 80:4169–4173.PubMedCrossRefGoogle Scholar
  80. 80.
    Muller, H.W, Gebicke-Harter, P.J., Hangen, D.H., Shooter, E.M. 1985. A specific 37,000-dalton protein that accumulates in regenerating but not in non-regenerating mammalian nerves. Science 228:499–501.PubMedCrossRefGoogle Scholar
  81. 81.
    Ignatius, M.J., Gebicke-Harter, P.J., Skene, J.H.P., et al. 1986. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. USA 83:1125–1129.PubMedCrossRefGoogle Scholar
  82. 82.
    Handelmann, G.E., Boyles, J.K., Weisgraber, K.H., Mahley, R.W., Pitas, R.E. 1992. Effects of apolipoprotein, β-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J. Lipid Res. 33:1677–1688.PubMedGoogle Scholar
  83. 83.
    Murakami, M., Yshio, Y., Morino, Y., Ohta, T., Matsukado, Y. 1988. Immunohistochemical localization of apolipoprotein E in human glial neoplasm. J. Clin. Invest. 82:177–188.PubMedCrossRefGoogle Scholar
  84. 84.
    Poirier, J., Hess, M., May, P.C., Finch, C.E. 1991. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Mol. Brain Res. 11:97–106.PubMedCrossRefGoogle Scholar
  85. 85.
    Pitas, R.E., Boyles, J.K., Lee, S.H., Foss, D., Mahley, R.W. 1987. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917:148–161.PubMedCrossRefGoogle Scholar
  86. 86.
    Boyles, J., Zoellner, C.D., Anderson, L.J., Kosik, L.M., Pitas, R.E., Weisgraber, K.H., Hui, D.Y., Mahley, R.W., Gebicke-Harter, P.J., Ignatius, M.J., Shooter, E.M. 1989. A role of apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J. Clin. Invest. 83:1015–1031.PubMedCrossRefGoogle Scholar
  87. 87.
    Boyles, J.K., Pitas, R.E., Wilson, E., Mahley, R.W., Taylor, J.M. 1985. Apolipoprotein E associated with astrocytic glia of the central nervous system and with non-myelinating glia of the peripheral nervous system. J. Clin. Invest. 76:1501–1513.PubMedCrossRefGoogle Scholar
  88. 88.
    Driscoll, D.M., Getz, G.S. 1984. Extrahepatic synthesis of apolipoprotein E. J. Lipid Res. 25:1368–1374.PubMedGoogle Scholar
  89. 89.
    Hussain, M.M., Bucher, N.L.R., Faris, B., Franzblau, C., Zannis, V.I. 1988. Tissue-specific post-translational modification of rat apoE synthesis of sialated apoE forms by neonatal rat aortic smooth muscle cells. J. Lipid Res. 29:915–923.PubMedGoogle Scholar
  90. 90.
    Zanni, E.E., Kouvatsi, A., Hadzopoulou-Cladaras, M., Krieger, M., Zannis, V.I. 1989. Expression of apoE gene in Chinese hamster cells with a reversible defect in O-glycosylation. Glycosylation is not required for apoE secretion. J. Biol. Chem. 264:9137–9140.PubMedGoogle Scholar
  91. 91.
    Wernette-Hammond, M.E., Lauer, S.J., Corsini, A., Walker, D., Taylor, J.M., Rall, Jr., S.C. 1989. Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. J. Biol. Chem. 264:9094–9101.PubMedGoogle Scholar
  92. 92.
    Hussain, M.M., Zanni, E.E., Kelly, M., Zannis, V.I. 1989. Synthesis, modification and flotation properties of rat hepatocyte apolipoproteins. Biochim. Biophys. Acta 101, 90–101.Google Scholar
  93. 93.
    Hussain, M.M., Roghani, A., Cladaras, C., Zanni, E.E., Zannis, V.I. 1991. Secretion of lipid poor nascent human apoA-I, apoCIII and apoE by cell clones expressing the corresponding genes. Electrophoresis 12:273–283.PubMedCrossRefGoogle Scholar
  94. 94.
    Pitas, R.E., Innerarity, T.L., Mahley, R.W. 1980. Cell surface receptor binding of phospholipid-protein complexes containing different ratios of receptor-active and inactive E apoprotein. J. Biol. Chem. 255:5454–5460.PubMedGoogle Scholar
  95. 95.
    Rebeck, W.G., Reiter, J.S., Strickland, D.K., Hyman, B.T. 1993. E in sporadic Alzheimer’s disease: Allelic variation and receptor interactions Neuron 11:575–580.PubMedCrossRefGoogle Scholar
  96. 96.
    Handelmann, G.E., Boyles, J.K., Weisgraber, K.H., Mahley, R.W., Pitas, R.E. 1992. Effects of apolipoprotein E, β-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J. Lipid Res. 33:1677–1688.PubMedGoogle Scholar
  97. 97.
    Wolf, B.B., Lopes, M.B., VandenBerg, S.R., Gonias, S.L. 1992. Characterization and immunohistochemical localization of a-2-macroglobulin receptor (low density lipoprotein receptor-related protein) in human brain. Am. J. Pathol. 141:37–42.PubMedGoogle Scholar
  98. 98.
    Tooyama, I., Kawamata, T., Akiyama, H., Moestrup, S.K., Gliemann, J., McGeer, P. 1993. Immunohistochemical study of a2-macroglobulin receptor in Alzheimer and control postmortem human brain. Mol. Chem. Neuropathol. 18:153–159.PubMedCrossRefGoogle Scholar
  99. 99.
    Takahashi, S., Kawarabayasi, Y., Nakai, T., Sakai, J., Yamamoto, T. 1992. Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. USA 89:9252–9256.PubMedCrossRefGoogle Scholar
  100. 100.
    Okuizumi, K., Onodera, O., Namba, Y., Ikeda, K., Yamamoto, T., Seki, K., Ueki, A., Nanko, S., Tanaka, H., Takahashi, H., Oyanagi, K., Mizusawa, H., Kanazawa I., Tsuji, S. 1995. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer’s disease. Nature Genet. 11:207–209.PubMedCrossRefGoogle Scholar
  101. 101.
    Wyne, K.L., Pathak, K., Seabra, M.C., Hobbs, H.H. 1996. Expression of the VLDL receptor in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 16:407–415.PubMedCrossRefGoogle Scholar
  102. 102.
    Innerarity, T.L., Friedlander, E.J., Rall, Jr., S.C., Weisgraber, K.H., Mahley, R.W. 1983. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J. Biol. Chem. 258:12341–12347.PubMedGoogle Scholar
  103. 103.
    Weisgraber, K.H., Innerarity, T.L., Harder, K.J., Mahley, R.W. Milne, R.W., Marcel, Y.L. J.T. Sparrow, J.T. 1983. The receptor-binding domain of human apolipoprotein E. J. Biol. Chem. 258:12348–12354.PubMedGoogle Scholar
  104. 104.
    Pitas, R.E., Innerarity, T.L., Mahley, R.W. 1980. Cell surface receptor binding of phospholipid-protein complexes containing different ratios of receptor-active and inactive E apoprotein. J. Biol. Chem. 255:5454–5460.PubMedGoogle Scholar
  105. 105.
    Lalazar, A., Weisgraber, K.H., Rall Jr., S.C., Giladi, H., Innerarity, T.L., Levanon, A.Z., Boyles, J.K., Amit, B., Gorecki, M., Mahley, R.W. 1988. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J. Biol. Chem. 263:3542–3545.PubMedGoogle Scholar
  106. 106.
    Weisgraber, K.H., Rall, Jr., S.C., Mahley, R.W., Milne, R.W., Marcel, Y.L., Sparrow, J.T. 1986. Human apolipoprotein E. J. Biol. Chem. 261:2068–2076.PubMedGoogle Scholar
  107. 107.
    Cardin, A.D., Hirose, N., Blankenship, D.T., Jackson, R.L., Harmony, J.A.K. 1986. Binding of a high reactive heparin to human apolipoprotein E: Identification of two heparin-binding domains. Biochem. Biophys. Res. Commun. 134:783–789.PubMedCrossRefGoogle Scholar
  108. 108.
    Ji, Z-S., Fazio, S., Lee, Y-L., Mahley, R.W. 1994. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J. Biol. Chem. 269:2764–2772.PubMedGoogle Scholar
  109. 109.
    Aggerbeck, L.P., Wetterau, J.R., Weisgraber, K.H., Wu, C.S.C., Lindgren, F.T. 1988. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino-and carboxyl-terminal domains. J. Biol. Chem. 263:6249–6258.PubMedGoogle Scholar
  110. 110.
    Weisgraber, K.H. 1990. Apolipoprotein E distribution among human plasma lipoproteins: Role of the cysteine-arginine interchange at residue 112. J. Lipid Res. 31:1503–1511.PubMedGoogle Scholar
  111. 111.
    Dong, L.-M., Weisgraber, K.H. 1996. Human apolipoprotein E4 domain interaction. J. Biol. Chem. 271:19053–19057.PubMedCrossRefGoogle Scholar
  112. 112.
    Westerlund, J.A., Weisgraber, K.H. 1994. Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J. Biol. Chem. 268:15745–15750.Google Scholar
  113. 113.
    Zannis, V.I., Just, P.W., Breslow, J.L. 1981. Human apolipoprotein E isoprotein subclasses are genetically determined. Am. J. Hum. Genet. 33:11–24.PubMedGoogle Scholar
  114. 114.
    Zannis, V.I., Breslow, J.L., Utermann, G., Mahley, R.W., Weisgraber, K.H., Havel, R.J., Goldstein, J.L., Brown, M.S., Schonfeld, G., Hazzard, W.R., Blum, C.B. 1982. Proposed nomenclature of apoE isoprotein genotypes and phenotypes. J. Lipid Res. 23:911–914.PubMedGoogle Scholar
  115. 115.
    Zannis, V.I., Breslow, J.L. 1981. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and post-translational modification. Biochemistry 20:1033–1041.PubMedCrossRefGoogle Scholar
  116. 116.
    Davignon, J., Gregg, R.E., Sing, C.F. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1–21.PubMedCrossRefGoogle Scholar
  117. 117.
    Rall, Jr., S.C., Weisgraber, K.H., Innerarity, T.L., R.W. 1982. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc. Natl. Acad. Sci. USA 79:4696–4703.PubMedCrossRefGoogle Scholar
  118. 118.
    Weisgraber, K.H., Innerarity, T.L., Mahley, R.W. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257:2518–2521.PubMedGoogle Scholar
  119. 119.
    Mahley, R.W., Innerarity, T.L., Rall, Jr., S.C., Weisgraber, K.H., Taylor, J.M. 1990. Apolipoprotein E: genetic variants provide insights into its structure and function. Curr. Opin. Lipidol. 1:87–95.CrossRefGoogle Scholar
  120. 120.
    Dong, L.-M., Parkin, S., Trakhanov, S.D., Rupp, B., Simmons, T., Arnold, K.S., Newhouse, Y.M., Innerarity, T.L., Weisgraber, K.H. 1996. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nature Struc. Biol. 3:718–722.CrossRefGoogle Scholar
  121. 121.
    Wardell, M.R., Brennan, S.O., Janus, E.D., R. Fraser, R., Carrell, R.W. 1987. Apolipoprotein E2-Christchurch (136 Arg—Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J. Clin. Invest. 80:483–490.PubMedCrossRefGoogle Scholar
  122. 122.
    Rall, S.C. Jr., Newhouse, Y.M., Clarke, H.R.G., Weisgraber, K.H., McCarthy, B.J., Mahley, R.W., Bersot, T.P. 1989. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3: structure and genetics of an apolipoprotein E3 variant. J. Clin. Invest. 83:1095–1101.PubMedCrossRefGoogle Scholar
  123. 123.
    Mann, W.A., Gregg, R.E., Sprecher, D.L., Brewer, Jr., H.B. 1989. Apolipoprotein E-1 Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochim. Biophys. Acta 1005:239–244.PubMedCrossRefGoogle Scholar
  124. 124.
    Wardell, M.R., Weisgraber, K.H., Havekes, L.M., Rall, Jr., S.C. 1989. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121–127. J. Biol. Chem. 264:21205–21210.PubMedGoogle Scholar
  125. 125.
    van den Maagdenberg, A.M., de Knijff, P., Stalenhoef, A.F., Gevers Leuven, J.A., Havekes, L.M., Frants, R.R. 1989. Apolipoprotein,3-Leiden allele results from a partial gene duplication in exon 4. Biochem. Biophys. Res. Commun. 165:851–857.PubMedCrossRefGoogle Scholar
  126. 126.
    Smit, M., de Knijff, P., van der Kooij-Meijs, E., Groenendijk, C., van den Maagdenberg, A.M., Gevers Leuven, J.A., Stalenhoef, A.F., Stuyt, P.M., Frants, R.R., Havekes, L.M. 1990. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2 (lys 146—gln) variant results in a dominant mode of inheritance. J. Lipid Res. 31:45–53.PubMedGoogle Scholar
  127. 127.
    Ghiselli, G., Schaefer, E.J., Gascon, P., Brewer Jr., H.B. 1981. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 214:1239–1241.PubMedCrossRefGoogle Scholar
  128. 128.
    Schaefer, E.J., Gregg, R.E., Ghiselli, G., Forte, T.M., Ordovas, J.M., Zech, L.A., Brewer, H.B. 1986. Familial apolipoprotein E deficiency. J. Clin. Invest. 78:1206–1219.PubMedCrossRefGoogle Scholar
  129. 129.
    Cladaras, C., Hadzopoulou-Cladaras, M., Felber, B.K., Pavlakis, G., Zannis, V.I. 1987. The molecular basis of a familial apoE deficiency. An acceptor splice site mutation in the third intron of the deficient apoE gene. J. Biol. Chem. 262:2310–2315.PubMedGoogle Scholar
  130. 130.
    Plump, A.S., Smith, J.D., Hayek, T., Aalto-Setala, K., Walsh, A., Verstuyft, J.D., Rubin, E.M., Breslow, J.L. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343–353.PubMedCrossRefGoogle Scholar
  131. 131.
    Piedrahita, J.A., Zhang, S.H., Hagaman, J.R., Oliver, P.M., Maeda, N. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA 89:4471–4475.PubMedCrossRefGoogle Scholar
  132. 132.
    Zhang, S.H., Reddick, R.L., Piedrahita, J.A., Maeda, N. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 2588:468–471.CrossRefGoogle Scholar
  133. 133.
    Reddick, R.L., Zhang, S.H., Maeda, N. 1994. Atherosclerosis in mice lacking apoE. Evaluation of lesional development and progression. Arterioscler. Thromb. 14:141–147.PubMedCrossRefGoogle Scholar
  134. 134.
    Van den Maagdenberg, A.M.J., Hofker, M.H., Krimpenfort, P.J.A., DeBruijn, I., Van Vlijmen, B., vander Boom, H., Havekes, L.M., Frants, R.R. 1993. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268:10540–10545.PubMedGoogle Scholar
  135. 135.
    Fazio, S., Lee, Y., Sheng, X., Rall, Jr., S.C. 1993. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein. J. Clin. Invest. 92:1497–1503.PubMedCrossRefGoogle Scholar
  136. 136.
    Fazio, S., Horie, Y., Simonet, W.S., Weisgraber, K.H., Taylor, J.M., Rall, Jr., S.C. 1994. Altered lipoprotein metabolism in transgenic mice expressing low levels of a human receptor-binding-defective apolipoprotein E variant. J. Lipid Res. 35:408–416.PubMedGoogle Scholar
  137. 137.
    Fazio, S., Sanan, D.A., Lee, Y.-L., Ji, Z.-S., Mahley, R.W., Rall, Jr., S.C. 1994. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E (Arg112, Cys142). Arterioscler. Thromb. 14:1873–1879.PubMedCrossRefGoogle Scholar
  138. 138.
    Huang, Y., Schwendner, S.W., Rall, Jr., S.C., Mahley, R.W. 1996. Hypolipidemia and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2*. J. Biol. Chem. 271:29146–29151.PubMedCrossRefGoogle Scholar
  139. 139.
    Shimano H., Yamada, N., Katsuki, M., Shimada, M., Gotoda, T., Harada, K., Murase, T., Fukazawa, C., Takaku, F., Yazaki, Y. 1992. Overexpression of apolipoprotein E in transgenic mice: Marked reduction in plasma lipoprotein except high density lipoprotein and resistance against diet-induced hypercholesterolemia. Proc. Natl. Acad. Sci. USA 89:1750–1754.PubMedCrossRefGoogle Scholar
  140. 140.
    Shimano H.N. Yamada, N., Katsuki, M., Yamamoto, K., Gotoda, T., Harada, K., Shimada, M., Yazaki, Y. 1992. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. J. Clin. Invest. 90:2084–2091.PubMedCrossRefGoogle Scholar
  141. 141.
    Pericak-Vance, M.A., Bebout, J.L., Gaskell Jr., P.C., Yamaoka, L.H., Hung, W.-Y., Alberts, M.J., Walker, A.P., Bartlett, R.J., Haynes, C.A., Welsh, K.A., Earl, N.L., Heyman, A., Clark, C.M., Roses, A.D. 1991. Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage. Am. J. Hum. Genet. 48:1034–1050.PubMedGoogle Scholar
  142. 142.
    Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., Ikeda, K. 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541:163–166.PubMedCrossRefGoogle Scholar
  143. 143.
    Wisniewski, T., Frangione, B. 1992. Apolipoprotein E: A pathological chaperon protein in patients with cerebral and systemic amyloid. Neuroscience Letters 135:235–238.PubMedCrossRefGoogle Scholar
  144. 144.
    Corder, E.H., Saunders, A.M., Risch, N.J., Strittmatter, W.J., Schmechel, D.E., Gaskell Jr., P.C., Rimmler, J.B., Locke, P.A., Conneally, P.M., Schmader, K.E., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A. 1994. Protective effect of apolipoprotein E type 2 allele for late-onset Alzheimer disease. Nature Genetics 7:180–184.PubMedCrossRefGoogle Scholar
  145. 145.
    Saunders, A.M., Strittmatter, W.J., Schmeehel, D., St. George-Hyslop, P.H., Pericak-Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper-MacLachlafl, D.R., Alberts, M.J., Hulette, C., Crain, B., Goldgaber, D., Roses, A.D. 1993. Association of apolipoprotein E allele,4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43:1467–1472.PubMedCrossRefGoogle Scholar
  146. 146.
    Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s diseases in late onset families. Science 261:921–923.PubMedCrossRefGoogle Scholar
  147. 147.
    Naslund, J., Thyberg, J., Tjernberg, L.O., Wernstedt, C., Karlstrom, A.R., Bodganovic, N., Gandy, S.E., Lannfelt, L. Terenius, L., Nordstedt, C. 1995. Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer’s disease brain. Neuron 15:219–228.PubMedCrossRefGoogle Scholar
  148. 148.
    Strittmatter, W.J., Weisgraber, K., Huang, D.Y., Dong, L.-M., Salvesen, G.S., Pericak-Vance, M., Schmechel, D., Saunders, A.M., Goldgaber, D., Roses, A.D. 1993. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:8098–8102.PubMedCrossRefGoogle Scholar
  149. 149.
    Zhou, Z., Smith, J.D., Greengard, P., Gandy, S. 1996. Alzheimer amyloid-β peptide forms denaturant-resistant complex with type E3 but not type E4 isoform of native apolipoprotein E. Molecul. Med. 2:175–180.Google Scholar
  150. 150.
    LaDu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, G.S., Frail, D.E. 1994. Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269:23403–23406.PubMedGoogle Scholar
  151. 151.
    LaDu, M.J., Pederson, T.M., Frail, D.E., Reardon, C.A., Getz, G.S., Falduto, M.T. 1995. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J. Biol. Chem. 9039-9042.Google Scholar
  152. 152.
    Strittmatter, W.J., Saunders, A.M., Goedert, M., Weisgraber, K.H., Dong, L.-M., Jakes, R., Huang, D., Pericak-Vance, M., Schmechel, D., Roses, A.D. 1994. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 91:11183–11186.PubMedCrossRefGoogle Scholar
  153. 153.
    Strittmatter, W.J., Roses, A.D. 1995. Apolipoprotein E and Alzheimer disease. Proc. Natl. Acad. Sci. USA 92:4725–4727.PubMedCrossRefGoogle Scholar
  154. 154.
    Huang, D.Y., Goedert, M., Jakes, R., Weisgraber, K.H., Garner, C.C., Saunders, A.M., Pericak-Vance, M.A., Schmechel, D.E., Roses, A.D., Strittmatter, W.J. 1994. Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2C: Implications for Alzheimer’s disease. Neurosci. Lett. 182:55–58.PubMedCrossRefGoogle Scholar
  155. 155.
    Wisniewski, T., Golabek, A., Matsubara, E., Ghiso, J., Frangione, B. 1993. Apolipoprotein E: Binding to soluble Alzheimer’s β-amyloid. Biochem. Biophys. Res. Commun. 192:359–365.PubMedCrossRefGoogle Scholar
  156. 156.
    Strittmatter, W.J., Weisgraber, K.H., Godert, M., Saunders, A.M., Huang, D., Corder, E.H., Dong, L.-M., Jakes, R., Alberts, M.J., Gilbert, J.R., Han, S.-H., Hulette, C., Einstein, G., Schmechel, D.E., Pericak-Vance, M.A., Roses, A.D. 1994. Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exper. Neurol. 125:163–171.CrossRefGoogle Scholar
  157. 157.
    Weisgraber, K.H., Mahley, R.W. 1996. Human apolipoprotein E: The Alzheimer’s disease connection. FASEB J. 10:1485–1494.PubMedGoogle Scholar
  158. 158.
    Matthews, D.A., Cotman, C., Lynch, G. 1976. An electron microscopic study of lesion-induced synaptogenesis in the dentate gyrus of the adult rat. I. Magnitude and time course of degeneration. Brain Research 115:1–21.PubMedCrossRefGoogle Scholar
  159. 159.
    Matthews, D.A., Cotman, C., Lynch, G. 1976. An electron microscopic study of lesion-induced synaptogenesis in the dentate gyrus of the adult rat. II. Reappearance of morphologically normal synaptic contacts. Brain Research 115:23–41.PubMedCrossRefGoogle Scholar
  160. 160.
    Poirier, J., Baccichet, A., Dea, D., Gauthier, S. 1993. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55:81–90.PubMedCrossRefGoogle Scholar
  161. 161.
    Flood, D.G., Coleman, P.D. 1986. Failed compensatory dendritic growth as a pathophysiological process in Alzheimer’s disease. Can. J. Neurol. Sci. 13:475–479.PubMedGoogle Scholar
  162. 162.
    Ransmayr, G., Cervera, P., Hirsch, E., Ruberg, M., Hersh, L.B., Duyckaerts, C., Hauw, J.-J., Delumeau, C., Agid, Y. 1989. Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer’s disease. Neuroscience 32:701–714.PubMedCrossRefGoogle Scholar
  163. 163.
    Nathan, B.P., Bellosta, S., Sanan, D.A., Weisgraber, K.H., Mahley, R.W., Pitas, R.E. 1994. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264:850–852.PubMedCrossRefGoogle Scholar
  164. 164.
    Nathan, B.P., Chang, K.-C., Bellosta, S., Brisch, E., Ge, N., Mahley, R.W., Pitas, R.E. 1995. The inhibitory effect of apolipoprotein E4 in neurite outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270:19791–19799.PubMedCrossRefGoogle Scholar
  165. 165.
    Bellosta, S., Nathan, B.P., Orth, M., Dong, L.-N., Mahley, R.W., Pitas, R.E. 1995. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem. 270:27063–27071.PubMedCrossRefGoogle Scholar
  166. 166.
    Beisiegel, U., Weber, W., Heeren, J., Hilpert, J. 1995. Intracellular consequences of chylomicron uptake. Circulation 92:691.Google Scholar
  167. 167.
    Han, S.-H., Einstein, G., Weisgraber, K.H., Strittmatter, W.J., Saunders, A.M., Pericak-Vance, M., Roses, A.D., Schmechel, D.E. 1994. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: A light and electron microscopic study. J. Neuropath. Exper. Neurol. 53:535–544.CrossRefGoogle Scholar
  168. 168.
    Poirier, J., Delisle, M.C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., Gilfix, B.M., Gauthier, S. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. USA 92:12260–12264.PubMedCrossRefGoogle Scholar
  169. 169.
    Poirier, J. 1994. Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci. 17:525–530.PubMedCrossRefGoogle Scholar
  170. 170.
    Soininen, H., Kosunen, O., Helisalmi, S., Mannermaa, A., Paljdrvi, L., Talasniemi, S., Ryyndnen, M., Sr, P.R. 1995. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein,4 allele. Neurosci. Lett. 187:79–82.PubMedCrossRefGoogle Scholar
  171. 171.
    Etienne, P., Robitaille, Y., Wood, P., Gauthier, S., Nair, N.P.V., Quirion, R. 1986. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer’s disease. Neuroscience 19:1279–1291.PubMedCrossRefGoogle Scholar
  172. 172.
    Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., DeLong, M.R. 1982. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237–1239.PubMedCrossRefGoogle Scholar
  173. 173.
    de Ruiter, J.P., Uylings, J.B.M. 1987. Morphometric and dendritic analysis of fascia dentata granule cells in human aging and senile dementia. Brain Res. 402:217–229.PubMedCrossRefGoogle Scholar
  174. 174.
    Bertrand, P., Poirier, J., Oda, T., Finch, C.E., Pasinetti, G.M. 1995. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol. Brain Res. 33:174–178.PubMedCrossRefGoogle Scholar
  175. 175.
    Roheim, P.S., Carey, M., Forte, T., Vega, G.L. 1979. Apolipoproteins in human cerebrospinal fluid. Proc. Natl. Acad. Sci. USA 76:4646–4649.PubMedCrossRefGoogle Scholar
  176. 176.
    Nitsch, R.M., Blusztajn, J.K., Pitas, A.G., Slack, B.E., Growdon, J.H., Wurtman, R.J. 1992. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA 89:1671–1675.PubMedCrossRefGoogle Scholar
  177. 177.
    Wurtman, R.J. 1992. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci. 15:117–122.PubMedCrossRefGoogle Scholar
  178. 178.
    Arendt, T., Schindler, C., Bruckner, M.K., Eschrich, K., Bigl, V., Zedlick, D., Marcova, L. 1997. Plastic neuronal remodeling is impaired in patients with Alzheimer’s disease carrying apolipoprotein E4 allele. J. Neurosci. 17:516–529.PubMedGoogle Scholar
  179. 179.
    Pillott, T., Goethals, M., Vanloo, B., Talussot, C., Brasseur, R., Vandekerckhove, J., Rosseneu, M., Lins, L. 1996. Fusogenic properties of the C-terminal domain of the Alzheimer β-amyloid peptide*. J. Biol. Chem. 271:28757–28765.CrossRefGoogle Scholar
  180. 180.
    Pillot, T., Goethals M., Vanloo B., Lins L., Brasseur R., L., Vandekerckhove, J., Rosseneu, M. 1996. Specific modulation of the fusogenic properties of the Alzheimer β-amyloid peptide by apolipoprotein E isoforms. Eur. J. Biochem. in press, 1997.Google Scholar
  181. 181.
    McLaurin, J., Chakrabarty, A. 1996. Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. J. Biol. Chem. 271:26482–26489.PubMedCrossRefGoogle Scholar
  182. 182.
    Miyata, M., Smith, J.D. 1996. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nature Genet. 14:55–61.PubMedCrossRefGoogle Scholar
  183. 183.
    Chartier-Harlin, M.-C., Parfitt, M., Legrain, S., Perez-Tur, J., Brousseau, T., Evans, A., Berr, C., Vidal, O., Roques, P., Gourlet, V., Fruchart, J.-C., Delacourte, A., Rossor, M., Amouyel, P. 1994. Apolipoprotein E, ε4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: Analysis of the 19q13.2 chromosomal region. Hum. Molec. Genet. 3:569–574.PubMedCrossRefGoogle Scholar
  184. 184.
    Corder, E.H., Saunders, A.M., Risch, N.J., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Jr., Rimmler, J.B., Locke, P.A., Conneally, P.M., Schmader, K.E., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A. 1994. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 7:180.PubMedCrossRefGoogle Scholar
  185. 185.
    Aleshkov, S.A., Abraham, C.R., Zannis, V.I. 1996. Complex formation of apoE produced by mammalian cells with amyloid peptide β (Aβ) follows the order apoE3>apoE3>>apoE4. 26th Annual Meeting, Society for Neuroscience 22:1696.Google Scholar
  186. 186.
    Zannis, V.I., Kurnit, D., Breslow, J.L. 1982. Hepatic apoA-I and apoE and intestinal apoA-I are synthesized in precursor isoprotein forms by organ cultures of human fetal tissues. J. Biol. Chem. 257:536–544.PubMedGoogle Scholar
  187. 187.
    Zannis, V.I., Ordovas, J.M., Cladaras, C., Cole, F.S., Forbes, G., Schaefer, E.J., 1985. mRNA and apolipoprotein E synthesis abnormalities in peripheral blood monocyte macrophages in familial apolipoprotein E deficiency. J. Biol. Chem. 24:12891–12894.Google Scholar
  188. 188.
    Zannis, V.I., van der Spek, J., Silverman, D. 1986. Intracellular modifications of human apolipoprotein E. J. Biol. Chem. 261:13415–13421.PubMedGoogle Scholar
  189. 189.
    Li, W.H. Tanimura, M., Luo, C.C., Datta, S., Chan, L. 1988. The apolipoprotein multigene family: Biosynthesis, structure, structure-function relationships and evolution. J. Lipid Res. 29:245–271.PubMedGoogle Scholar
  190. 190.
    Innerarity, T.L., Pitas, R.E., Mahley, R.W. 1979. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J. Biol. Chem. 254:4186–4190.PubMedGoogle Scholar
  191. 191.
    Laggner, P., Gotto, Jr., A.M., Morrisett, J.D. 1977. Physical properties of the dimyristoylphosphatidylcholine vesicle and the complex formed by its interaction with apolipoprotein CIII: X-ray single angle scattering studies. Biochemistry 18:164–171.CrossRefGoogle Scholar
  192. 192.
    Higgins, L.S., Rodems, J.M., Catalano, R., Quon, D., Cordell, B. 1995. Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for b-APP751. Proc. Natl. Acad. Sci. USA 92:4402–4406.PubMedCrossRefGoogle Scholar
  193. 193.
    Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., Cole, G. 1996. Correlative memory deficits and amyloid plaques in transgenic mice. Science 274:99.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Vassilis I. Zannis
    • 1
  • Eleni E. Zanni
    • 1
  • Savvas C. Makrides
    • 1
  • Dimitris Kardassis
    • 2
  • Sergei Aleshkov
    • 1
  1. 1.Section of Molecular Genetics, Center for Advanced Biomedical Research, Departments of Medicine and BiochemistryBoston University Medical CenterBostonUSA
  2. 2.Department of BiochemistryUniversity of Crete School of MedicineHeraklion, CreteGreece

Personalised recommendations